Uveitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 176 Published: June 30, 2022 Report Code: GDGMDHC22232IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis – Drugs In Development, 2022, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 8, 8, 1, 45 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • ABIONYX Pharma SA

    Acelyrin Inc

    Aciont Inc

    Active Biotech AB

    Aerie Pharmaceuticals Inc

    Akari Therapeutics Plc

    Aldeyra Therapeutics Inc

    Alpine Immune Sciences Inc

    Alvotech ehf

    Amytrx Therapeutics Inc

    Avirmax Inc

    BioMarck Pharmaceuticals Ltd

    BioNanoSim Ltd

    Bonac Corp

    Cellivery Therapeutics Inc

    Celltrion Inc

    Chugai Pharmaceutical Co Ltd

    Dobecure SL

    E&B Technologies LLC

    Elasmogen Ltd

    Enzo Biochem Inc

    EyePoint Pharmaceuticals Inc

    Eyevensys SAS

    F. Hoffmann-La Roche Ltd

    HanAll Biopharma Co Ltd

    IACTA Pharmaceuticals Inc

    iCELL Biotechnology Co Ltd

    Inovio Pharmaceuticals Inc

    Juvenescence UK Ltd

    Kiora Pharmaceuticals Inc

    Kodiak Sciences Inc

    Kriya Therapeutics Inc

    Kubota Vision Inc

    MeiraGTx Holdings Plc

    Mitotech SA

    Naegis Pharmaceuticals Inc

    NeuClone Pty Ltd

    Novaliq GmbH

    Novartis AG

    Oculis SA

    OKYO Pharma Ltd

    OncoNOx ApS

    ONL Therapeutics Inc

    Orchid Pharma Ltd

    OSE Immunotherapeutics SA

    Oxular Ltd

    Palatin Technologies Inc

    Panag Pharma Inc

    Parvus Therapeutics Inc

    Pharmapraxis

    Reven Holdings Inc

    Revolo Biotherapeutics Ltd

    RiniSight Inc

    Ripple therapeutics Corp

    SFA Therapeutics Inc

    Shanghai Henlius Biotech Inc

    Shennong Biotech Inc

    Skye Bioscience Inc

    Sol-Gel Technologies Ltd

    Tarsius Pharma Ltd

    Tianjin Pharmaceuticals Group Co Ltd

    Topas Therapeutics GmbH

    Valitor Inc

    Vyome Therapeutics Inc

    Worg Pharmaceuticals Hangzhou Co Ltd

    Wuhan Healthgen Biotechnology Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uveitis – Overview

Uveitis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uveitis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uveitis – Companies Involved in Therapeutics Development

Uveitis – Drug Profiles

Uveitis – Dormant Projects

Uveitis – Discontinued Products

Uveitis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Uveitis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Uveitis – Dormant Projects, 2022

Uveitis – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Uveitis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.